PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Latest Episodes:

Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors? Jan 11, 2023

Show notes

Go online to PeerView.com/HFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an interprofessional panel of experts examines the efficacy and safety data for HIF-PH inhibitors in the treatment of CKD-associated anemia and discusses best practices for working collaboratively with other members of the healthcare team to identify patients with CKD who are at risk for anemia The panel also considers current and emerging treatment strategies that pharmacists can use to improve the clinical management of CKD-associated anemia. Upon completion of this activity, participants should be better able to: Describe the rationale for involving clinical pharmacists in the management of anemia associated with CKD; Differentiate the mechanisms of action of HIF-PH inhibitors from other treatments for anemia associated with CKD; Evaluate the clinical potential of HIF-PH inhibitors as an emerging treatment approach for anemia in patients with DD-CKD or NDD-CKD; ad Apply evidence-based strategies within the context of health-system pharmacy to identify patients with CKD-associated anemia who would likely benefit from treatment with a HIF-PH inhibitor.

Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All Jan 06, 2023

Show notes

Go online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, a panel of leading bladder cancer experts pairs important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity will highlight strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for the use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Using patient cases drawn from clinical practice and interactivity that allows participants to see how their treatment choices compare with their colleagues, the faculty will address the mechanistic rationale for these new therapies, therapeutic decision-making, and AE mitigation strategies. Upon completion of this activity, participants should be better able to: Synthesize new evidence on multi-faceted strategies for bladder cancer management based on modern immunotherapeutic agents, small molecule targeted therapies, and antibody–drug conjugates, among others; Integrate novel and emerging therapeutic approaches into personalized treatment plans for patients with bladder cancer, considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Implement evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer

Rana R. McKay, MD, Alicia K. Morgans, MD, MPH - Alicia K. Morgans, MD, MPH - Case by Case: Maximizing Personalized Approaches to Prostate Cancer Jan 06, 2023

Show notes

Go online to PeerView.com/YGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The expanding therapeutic landscape for prostate cancer has provided new opportunities for oncology and urology professionals to improve outcomes through individualized patient care. With new and emerging strategies in both the hormone-sensitive and -resistant settings, treatment of patients with prostate cancer requires knowledge of next-generation anti-androgen agents, PARP inhibitors, and use of immunotherapy, radioligands, and other strategies alone or in active combinations, along with guidelines for testing and treatment. In this activity, urologic oncology experts pair in-depth analysis of efficacy and safety evidence with a case-focused discussion of best practices for bringing treatment advances to the clinic. Featured topics include novel therapeutic approaches, strategies for collaboration with other clinicians and patients to optimize care, and the role of clinical trials. Upon completion of this activity, participants should be better able to: Incorporate guideline-recommended germline and somatic testing into the routine management of patients with prostate cancer to inform therapeutic decision-making; Describe the therapeutic roles, key efficacy and safety evidence, and current guideline recommendations pertaining to the use of novel and emerging prostate cancer treatment strategies; and Develop individualized treatment algorithms that incorporate new data and treatment options (including clinical trial enrollment), expert recommendations, shared decision-making, and multidisciplinary team-based care for patients with prostate cancer

Professor Peter Schmid, FRCP, MD, PhD - TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments Jan 06, 2023

Show notes

Go online to PeerView.com/ZDH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel antibody–drug conjugates (ADCs) represent a much-needed addition of highly effective agents with unique mechanisms of action to the breast cancer treatment arsenal. TROP2-targeted ADC therapy already has an established role in triple-negative breast cancer (TNBC), and it has recently also demonstrated activity in HR+/HER2- breast cancer. Further investigations are underway in earlier disease settings and in various rational combinations. How can you make the most of these new ADC options in the context of other available therapies, and what is the best way to integrate them into practice? This activity, based on a PeerView Live MasterClass & Practicum educational symposium, addresses these and many other critical questions. By combining insightful analyses of the most recent data with compelling discussions of cases and practicalities, our international expert panel helps you better navigate the complex clinical decisions about when and how to use TROP2-targeting ADCs and the other latest therapies in real-world settings of breast cancer. Upon completion of this activity, participants should be better able to: Describe the rationale, mechanism of action, evolving clinical role, and latest safety and efficacy evidence on TROP2-targeting agents in the treatment of different subtypes of breast cancer, including TNBC and HR+ breast cancer; Integrate personalized treatment plans for patients with breast cancer that takes into consideration the latest evidence and guidelines on TROP2-targeting therapies and relevant treatment-, disease-, and patient-specific factors; and Apply a patient-centered approach to care that incorporates shared decision-making, patient education, and engagement that leverages effective multidisciplinary collaboration and care coordination

Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events Jan 04, 2023

Show notes

Go online to PeerView.com/SFP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) have had a strikingly positive impact on the treatment of a range of cancer types by blocking intrinsic downregulators of the immune response to increase antitumor immunity. A number of ICIs and ICI-based combinations have been approved for use in many solid and liquid malignancies, and intense research efforts promise to expand their role in advanced cancers and early-stage, curative-intent settings. While immunotherapy has become a pillar of cancer treatment and is considered safe, ICIs are associated with a spectrum of unique toxicities termed immune-related adverse events (irAEs). These irAEs can affect any organ system in the body, including the heart and cardiovascular system, occur at any point during or after treatment, and vary in presentation from mild to severe, and sometimes life threatening. Cardiac pathology attributed to irAEs include myocarditis, cardiomyopathy, pericardial disease, arrhythmias and conduction disease, impaired ventricular function with heart failure, and vasculitis. Autoimmune myocarditis is the most common and best characterized cardiac irAE to date. This activity, based on a PeerView Live Clinical Consults cardio-oncology symposium, provides essential guidance for prompt identification and initiation of treatment of irAEs. In the current era of cancer immunotherapy, healthcare professionals must develop a high level of vigilance and be able to correctly and rapidly manage and monitor patients with cancer exhibiting symptoms of possible cardiac irAEs to ensure the best possible outcomes. The expert faculty presents management algorithms, real-world case scenarios, and practical challenges related to multidisciplinary coordination of care to improve collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Review the prevalence, biologic mechanisms, burden, and consequences of the development of cardiac immune-related adverse events (irAEs) during or after treatment with cancer immunotherapies; Apply algorithms, practical tools, and available therapies based on the latest clinical evidence and recommendations for baseline risk assessment, identification, diagnosis/differential diagnosis, treatment, and management of cardiac irAEs; and Utilize effective shared decision-making and team-based approaches to facilitate multidisciplinary and interprofessional collaboration and improve clinician-patient communication and outcomes for patients at risk of or experiencing cardiac irAEs

Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE? Dec 19, 2022

Show notes

Go online to PeerView.com/HBR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this MasterClass series, two leading experts on venous thromboembolism (VTE) discuss the diagnosis and management of deep vein thrombosis (DVT) and pulmonary embolism (PE). Upon completion of this activity, participants should be better able to: Apply evidence-based tools to improve the identification of patients at risk for VTE; Implement the latest evidence-based guidelines to determine eligibility and duration of appropriate treatment regimens for individual patients with or at risk for VTE, including those with obesity and/or cancer; Counsel patients, including those with obesity and/or cancer, about the risks of VTE and the comparative efficacy and safety associated with different anticoagulation therapies for reducing the risk of and managing VTE; and Incorporate evidence-based, collaborative strategies for interprofessional and multidisciplinary care teams to identify, treat, follow up, and/or refer patients with or at risk for VTE.

Maureen A. McMahon, MD - How I Think, How I Treat—Assessing, Managing, and Engaging Patients to Optimize Care in SLE and LN: Comparing Approaches With the Experts Dec 19, 2022

Show notes

Go online to PeerView.com/TSR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, an expert panel examines the latest evidence for currently approved targeted agents in systemic lupus erythematosus (SLE) and lupus nephritis (LN) and offers personal anecdotes and reflections to illustrate how scientific findings can inform everyday clinical practices and guide individualized approaches to care. Additionally, the panel discusses the need for culturally competent care to ameliorate healthcare disparities offering evidence-based tools and tactics to overcome barriers and improve access to care and health information needs for patients in marginalized populations. Upon completion of this activity, participants should be better able to: Employ best practices related to the diagnosis and assessment of SLE and LN; Describe the pathophysiology of SLE and LN, recognizing targets for therapeutic intervention; Outline the mechanism of action, efficacy, and safety of current targeted therapies for SLE and LN; Select appropriate pharmacologic therapy for individual patients with SLE and LN to ensure long-term survival, achieve the lowest possible disease activity, prevent organ damage, minimize drug toxicity, and improve quality of life; and Deliver patient-centered and culturally competent care to improve the management of symptoms and promote adherence to long-term treatment in patients with SLE and LN.

Amit Singal, MD, MS - It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration / Modern Therapeutics Dec 19, 2022

Show notes

Go online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improve patient outcomes. Designed to guide professionals into a new era of team-based personalized care, this Seminars & Tumor Board activity features a multidisciplinary panel of experts who will link current science and treatment recommendations to practical guidance on therapeutic decision-making. Using case-based discussion, the expert panel will address a variety of clinical issues such as treatment selection, sequencing, and the integration of systemic therapy with locoregional management. It takes a team to provide the best care for your patients—participate in this activity to hear the latest on using collaborative strategies to optimize outcomes in HCC. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of novel and emerging systemic therapy approaches for patients with advanced/metastatic HCC; Review the latest evidence on innovative strategies, including novel locoregional modalities, combinations of locoregional and systemic therapies, and perioperative/conversion approaches, for patients with HCC across the disease continuum; Develop contemporary, personalized management plans for patients with HCC that consider the available clinical evidence, expert/guideline recommendations, clinical trial opportunities, and patient-, disease-, and treatment-specific factors; and Implement best practices for multidisciplinary collaboration and care coordination when managing patients with HCC, including team-based strategies to maximize treatment efficacy, safety, tolerability, and patient quality of life.

Sumanta Kumar Pal, MD, FASCO - RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World Dec 19, 2022

Show notes

Go online to PeerView.com/WYC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Robust clinical evidence supports effective upfront treatment platforms based on novel multitargeted tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitor therapies, now standard for patients with renal cell carcinoma (RCC). New options across the disease spectrum allow more patients with metastatic, refractory, or high-risk localized disease to benefit. In PeerView’s latest Clinical Consults video, an expert panel will share their insight for effectively integrating different treatment approaches linked to the latest evidence and expand upon real-life experiences and practical guidance. Upon completion of this activity, participants should be better able to: Evaluate evidence on the role of novel and emerging therapeutics, efficacy, and safety for patients with RCC; Formulate individualized treatment plans for patients with RCC that incorporate novel and emerging therapeutic approaches, latest evidence, and patient-, disease- and treatment-specific factors; and Integrate evidence-based strategies and best practices to recognize, mitigate, and manage the unique suite of adverse events associated with novel treatment approaches for patients with RCC

Catherine M. Broome, MD - Following the Diagnostic Pathway for Cold Agglutinin Disease Dec 19, 2022

Show notes

Go online to PeerView.com/UHP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), as well as appropriate strategies to differentiate cold agglutinin disease from other forms of AIHA in providing optimal care for patients. Upon completion of this activity, participants should be better able to: Recognize the main clinical features and pathophysiologic mechanisms of autoimmune hemolytic anemia (AIHA), and Employ appropriate strategies to differentiate cold agglutinin disease (CAD) from other forms of autoimmune hemolytic anemia (AIHA) to provide optimal care for patients.